MedTech startup Eyedentity has raised €1.3 million (SEK 15 million) in its first investment round. The funding round was oversubscribed, meaning more investors wanted to invest than the company originally planned to accept.
The funding round was led by Norrsken Launcher. Karolinska Institutet Innovation and several angel investors also participated in the round.
Eyedentity will use the new funding to work toward regulatory approval and continue developing its products. The company is building an AI-powered platform that helps with eye health diagnostics.
The startup plans to expand its technology into optician stores, eye clinics and hospitals. The goal is to make its AI-powered diagnostic tools available to more healthcare professionals and patients.
Gustav Stålhammar, co-founder and CSO of Eyedentity, says: “A huge number of images are already taken at opticians, and there is a trend that opticians in particular are getting an increasingly large group of patients, for example people seeking help for vision problems, dry eyes or other problems.”
Anna Fredrixon, Partner at Norrsken Launcher, adds: “This is a clear example of technology that can save lives but, unlike other AI companies, does not send more patients to an already overburdened healthcare system. This is a win-win. And what’s more, no new infrastructure is needed. It’s brilliant, and ready to roll out now.”
Founded in 2025, Eyedentity is developing AI technology that can help detect serious eye diseases using fundus images taken during routine eye check-ups.
Eyedentity’s first AI application focuses on uveal melanoma, a rare but serious type of eye cancer. It can be difficult to identify, especially in the early stages, because it can look similar to harmless eye conditions.
Uveal melanoma is the most common type of primary eye cancer in adults. However, it is still rare compared with many other types of cancer.
One of the biggest challenges is telling uveal melanoma apart from benign eye conditions. Since harmless conditions are much more common, accurate testing and early identification are important when routine eye scans show something unusual.
